Pharmacotheraphy for Alzheimer's disease.

Research output: Contribution to journalReview article

21 Scopus citations

Abstract

In the past 2 years, substantive advances in therapy for Alzheimer's disease (AD) have occurred. The nature of the effects of cholinesterase inhibitors has been refined with the publication of several studies that have examined different aspects of the symptomatology of AD. Breakthroughs in the basic science of Alzheimer's disease have led to new insights into potential therapeutic strategies targeted at the secretases involved in the metabolism of the Alzheimer precursor protein. An immunization approach, in which the beta-amyloid protein itself was used as the immunizing agent, has also been presented and independently validated. Other areas of investigation with disappointing results, such as estrogen replacement therapy, anti-inflammatory approaches, and several other therapeutic agents, are also reviewed.

Original languageEnglish (US)
Pages (from-to)428-434
Number of pages7
JournalCurrent neurology and neuroscience reports
Volume1
Issue number5
DOIs
StatePublished - Sep 2001

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Pharmacotheraphy for Alzheimer's disease.'. Together they form a unique fingerprint.

  • Cite this